简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Video
Research
HOME
·
Micot Pharma
Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment
Tags：
Micot Pharma
02335.HK
Clinical Trial
2026-07-09
Micot Pharma-B (02335.HK) Launches IPO: Max Offer Price at HK$21.0, Entry Fee Around HK$4,242 per Lot
Tags：
Micot Pharma
02335.HK
IPO
2026-06-15
Micot Pharma Passes HKEX Listing Hearing, Lead Candidate MT1013 in Phase III Clinical Trial
Tags：
Micot Pharma
IPO
pass the listing hearing
2026-06-05
Featured News
Research
HK Newly Listed Stocks Weekly Tracker: AUX ELECTRIC's 1.3 Billion-Share Lock-up Expiry Lands Softly; UNISOUND Leads Rebound in Newer Listings - 20260904
Research
Going Global Weekly Report: Pharma Firms Sealed Licensing Deals at a Fast Pace as Semiconductors and E-Commerce Accelerate toward HK Listings - 20260904
Research
HK Stock Connect Daily Report: PHANCY Surged Nearly 15%; Hang Seng Index Quarterly Review Effective Today, Goldman Sachs Expects USD 870 Million of Passive Inflows into Tech Hardware - 20260904
Research
Weekly Hong Kong ETFs Average Return Statistics (by Fund Manager) (Third Week of August 2026)
Research
Weekly Hong Kong ETFs Return Statistics (First Week of September 2026)
Finance
CBHB (09668.HK): Completes Issuance of RMB 15 Billion Financial Bonds
Finance
RAINMED-B (02297.HK): Wang Lin Resigns as Non-Executive Director; Lu Xun Appointed
Research
Weekly Shanghai-Shenzhen Stock Connect ETF Average Return Statistics (by Fund Manager) (First Week of September 2026)
Finance
KANGDA ENV (06136.HK): Completes Issuance of USD 50 Million 8.0% Senior Notes Due 2029
Research
Weekly Shanghai-Shenzhen Stock Connect ETFs Return Statistics (First Week of September 2026)
Scan QR Code
Download App
